EPIVIRHBV (GlaxoSmithKline LLC)
Welcome to the PulseAid listing for the EPIVIR drug offered from GlaxoSmithKline LLC. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | GlaxoSmithKline LLC |
| NON-PROPRIETARY NAME: | lamivudine |
| SUBSTANCE NAME: | LAMIVUDINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 1998-12-23 |
| END MARKETING DATE: | 0000-00-00 |
EPIVIR HBV HUMAN PRESCRIPTION DRUG Details:
| Item Description | EPIVIR HBV from GlaxoSmithKline LLC |
| LABELER NAME: | GlaxoSmithKline LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5(mg/mL) |
| START MARKETING DATE: | 1998-12-23 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0173-0663_3f46fa8c-6d88-4d25-b097-58400b784b31 |
| PRODUCT NDC: | 0173-0663 |
| APPLICATION NUMBER: | NDA021004 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers:
